Type 1 and type 2 diabetes share the symptom of high blood glucose but have fundamentally different causes. Type 1 is an autoimmune disease that destroys insulin-producing beta cells, requires lifelong insulin, and is not preventable. Type 2 is a combination of insulin resistance and relative insulin deficiency, makes up about 90 percent of cases, and is often preventable and sometimes reversible. Other subtypes — LADA, MODY, type 3c — exist and change management. Islet autoantibodies and C-peptide testing clarify the diagnosis when the clinical picture is unclear.
Side-by-Side Comparison
| Feature | Type 1 Diabetes | Type 2 Diabetes |
|---|---|---|
| Underlying cause | Autoimmune destruction of beta cells | Insulin resistance plus relative insulin deficiency |
| Share of all diabetes | ~5-10 percent | ~90-95 percent |
| Typical onset age | Childhood, adolescence, young adulthood — can occur at any age | Usually over age 35; rising in youth |
| Body composition | Often normal weight at diagnosis; weight loss may be present | Often overweight or obese; visceral adiposity |
| Family history | Less commonly direct first-degree relative; HLA-linked risk | Strong family history common |
| Islet autoantibodies | Positive (GAD65, IA-2, ZnT8, IAA) | Negative |
| C-peptide | Low or undetectable (after honeymoon) | Normal or elevated early; declines over years |
| Onset speed | Often rapid (weeks); DKA at diagnosis common | Usually gradual; can be silent for years |
| Treatment | Insulin (multiple daily injections or pump) lifelong | Lifestyle, metformin, GLP-1, SGLT2, others; insulin if needed |
| Reversibility | Not reversible | Often preventable; sometimes reversible early |
| DKA risk | High — needs sick-day rules and ketone testing | Lower (except on SGLT2 inhibitors) |
| Honeymoon period | Yes — temporary recovery of beta-cell function after diagnosis | No |
Type 1 Diabetes — In Depth
- Autoimmune attack on insulin-producing pancreatic beta cells
- Genetic susceptibility (HLA-DR3/DR4 haplotypes) plus environmental triggers (possibly viral infection, gut microbiome, vitamin D status)
- Absolute insulin deficiency — body cannot produce sufficient insulin
- Often presents acutely with weight loss, thirst, urination, DKA
- Honeymoon period: temporary partial recovery of beta-cell function in the first months after diagnosis
- Lifetime insulin therapy via multiple daily injections, insulin pump, or hybrid closed-loop system
- CGM (Dexcom G6/G7, FreeStyle Libre 2/3, Eversense) is standard of care
- Increased risk of celiac disease, autoimmune thyroid disease, Addison’s disease
- Teplizumab (Tzield) can delay onset by 2-3 years in at-risk relatives with positive antibodies and dysglycemia
Type 2 Diabetes — In Depth
- Insulin resistance — cells respond poorly to insulin
- Beta-cell dysfunction develops over years; relative insulin deficiency emerges
- Strong genetic predisposition (polygenic; family history)
- Environmental drivers: caloric excess, visceral adiposity, sedentary lifestyle, sleep deprivation, certain medications
- Often silent for years — diagnosed by routine screening or complication presentation
- First-line treatment: lifestyle (diet, activity, weight loss), metformin
- Add-on options: GLP-1 agonists (semaglutide, tirzepatide, dulaglutide, liraglutide), SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, insulin
- Sometimes reversible (remission) with substantial weight loss or bariatric surgery, especially in the first 1-3 years
- Strong cardiovascular and kidney comorbidities
Diagnostic Testing
| Test | Type 1 Result | Type 2 Result |
|---|---|---|
| A1C | Often very high at diagnosis | 6.5 percent or higher |
| Fasting plasma glucose | Often very high | ≥126 mg/dL |
| Random plasma glucose | Very high with symptoms | ≥200 mg/dL with symptoms |
| Islet autoantibodies (GAD65, IA-2, ZnT8, IAA) | Positive (at least one) | Negative |
| C-peptide | Low or undetectable | Normal or high early; falls over time |
| Genetic testing (HLA, MODY panel) | HLA-DR3/DR4 increases risk | Standard tests are not routine |
Other Types Worth Knowing
- LADA (latent autoimmune diabetes in adults) — adult-onset autoimmune diabetes, slower than classical type 1; often initially misdiagnosed as type 2; islet autoantibodies positive, C-peptide may be intermediate
- MODY (maturity-onset diabetes of the young) — single-gene forms of diabetes (HNF1A, HNF4A, GCK, others); young, lean patients with strong family history; specific treatments differ (some MODY responds to sulfonylureas, some need no treatment)
- Type 3c (pancreatogenic) diabetes — diabetes from pancreatic damage (pancreatitis, pancreatectomy, cystic fibrosis, pancreatic cancer); insulin-dependent with possible exocrine insufficiency
- Gestational diabetes — diabetes first recognized in pregnancy
- Drug- or steroid-induced diabetes — glucocorticoids, certain antipsychotics, immunosuppressants
- Monogenic neonatal diabetes — diagnosed before 6 months
Common Misconceptions
- “Type 1 is the bad one and type 2 is the easy one” — type 2 can cause as much or more complication burden; both are serious
- “Only kids get type 1” — adults can develop type 1 or LADA at any age
- “Only overweight people get type 2” — type 2 occurs in lean individuals, especially in Asian populations
- “Eating too much sugar causes type 1” — no, type 1 is autoimmune, not lifestyle-driven
- “Type 2 means I failed” — type 2 has strong genetic and environmental drivers; self-blame is not warranted
Treatment Differences
| Therapy | Type 1 | Type 2 |
|---|---|---|
| Insulin | Required from diagnosis lifelong | May be added when other agents insufficient |
| Metformin | Off-label; sometimes added for weight | First-line oral agent |
| GLP-1 agonists | Sometimes added off-label | FDA-approved; first-line in many algorithms |
| SGLT2 inhibitors | Use with caution — DKA risk | Approved; cardiovascular and kidney benefits |
| Pramlintide | FDA-approved adjunct | FDA-approved adjunct (less common) |
| Bariatric surgery | Generally not indicated for glycemic reversal | Highly effective for remission in eligible patients |
| Closed-loop insulin pump | Standard of care option | Available in select cases |
Reversibility and Remission
- Type 1 diabetes: not reversible — even successful islet or pancreas transplant requires immunosuppression
- Type 2 diabetes remission: A1C below 6.5 percent for at least 3 months without diabetes medications
- Best chance: within 1 to 3 years of diagnosis
- Approaches: 10-15+ percent body weight loss, low-calorie diet, low-carbohydrate diet, intensive lifestyle change (DiRECT trial), GLP-1 medications, bariatric surgery
- Remission is not cure — many people regain diabetes if weight is regained or beta-cell function declines further
- For more, see our guide on whether prediabetes is reversible
Complications
- Both types share the same major complications when poorly controlled: retinopathy, nephropathy, neuropathy, cardiovascular disease
- Type 1 has longer disease duration on average so early complications are concerning
- Type 2 often has cardiovascular and metabolic comorbidities (hypertension, dyslipidemia) at diagnosis
- See our overview of complications and related conditions
Related Reading
For comparison-type guides in this batch, see dawn phenomenon vs Somogyi effect and ketosis vs ketoacidosis. For foundational concepts, start with A1C levels and our treatment overview.
The Bottom Line
Type 1 and type 2 diabetes share high blood glucose but differ in cause, treatment, and prognosis. Type 1 is autoimmune destruction of insulin-producing beta cells — about 10 percent of cases, requires insulin from diagnosis, and is not reversible. Type 2 is insulin resistance plus relative insulin deficiency — about 90 percent of cases, often responds to lifestyle and medications, and can sometimes be put into remission early after diagnosis. LADA, MODY, type 3c, and other subtypes deserve specific testing when the clinical picture does not fit. Islet autoantibodies and C-peptide clarify the type when needed. Either way, early diagnosis and tight management protect against complications and support a long, healthy life.
